Role of Leukotriene Receptor Antagonists in the Management of Pediatric Asthma
First Online: 18 December 2012 DOI:
Cite this article as: Dumitru, C., Chan, S.M.H. & Turcanu, V. Pediatr Drugs (2012) 14: 317. doi:10.1007/BF03262237 Abstract
At present, the main indications for leukotriene receptor antagonists (LTRA) in pediatric asthma are as add-on therapy to inhaled corticosteroids (ICS) and as initial controller therapy in children with mild asthma, especially those who cannot or will not use ICS.
LTRA are also useful for patients who have concomitant rhinitis, and patients with viral-induced wheeze and exercise-induced asthma. It should be noted that the benefits of LTRA therapy have been demonstrated in children as young as 6 months of age and recent clinical trials have further proven the benefits of LTRA in acute asthma exacerbations.
However, considering the important pro-inflammatory effects that leukotrienes (LT) have in experimental models of asthma, it may seem surprising that LTRA treatment outcomes are not better and that in some clinical trials only a minority of patients could be classified as full responders. This could be explained by potential additional LT receptors that are not affected by LTRA. Such receptors could represent new therapeutic targets in asthma.
Furthermore, progress in differentiating between asthma phenotypes that result from different pathogenic mechanisms, some of which may involve LT to a lesser degree, should lead to an improved, personalized use of LTRA for treating asthma.
National Institutes of Health, National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. No. 07–4051 [online]. Available from URL:
[Accessed 2012 Jul 24]
Van den Akker-van Marle ME, Bruil J, Detmar SB. Evaluation of cost of disease: assessing the burden to society of asthma in children in the European Union. Allergy 2005; 60: 140–9.
Szefler SJ, Apter A. Advances in pediatric and adult asthma. J Allergy Clin Immunol 2005; 115:470–7.
Peters-Golden M, Henderson Jr WR, Leukotrienes. N Engl J Med 2007; 357: 1841–54.
Dahlen SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006; 533: 40–56.
Salvi SS, Krishna MT, Sampson AP, et al. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119: 1533–46.
Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006; 6: 414–20.
Kanoaka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004; 173: 1503–10.
Barnes PJ, Chung KF, Page CP. Inflammatory mediators in asthma: an update. Pharmacol Rev 1998; 50: 515–96.
Hay DWP, Torphy TJ, Undem RJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16: 304–9.
Dahlen SE, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288: 484–6.
Weiss JW, Drazen JM, Coles N, et al. Bronchoconstrictor effects of leukotriene C in humans. Science 1982; 216: 196–8.
Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Resp Crit Care Med 1997; 156: 737–43.
Capra V. Molecular and functional aspects of human cystenil leukotriene receptors. Pharmacol Res 2004; 50: 1–11.
Elias J, Lee CG, Zheng T, et al. New insights into the pathogenesis of asthma. J Clin Invest 2003; 111: 291–7.
Brightling CE, Bradding P, Symon FA, et al. Mast cell infiltration of airway smooth muscle in asthma. N Engl J Med 2003; 346: 1699–705.
Jeffrey PK, Laitnen A, Venge P. Biopsy markers of airway inflammation and remodelling. Respir Med 2000; 94: S9–15.
Dworsky R, Fitzgerald GA, Oates JA, et al. Effects of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 194: 953–9.
Henderson Jr WR, Chiang GK, Tien YT, et al. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Resp Crit Care Med 2006; 173: 718–28.
Kelly MM, Chakir J, Vethanayagam D, et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 2006; 130: 741–53.
Zyflo consumer information [online]. Available from URL:
[Accessed 2011 Aug 21]
Montuschi P, Sala A, Dahlén S-E, et al. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today 2007; 12:404–12.
Singulair® paediatric 4mg chewable tablets: summary of product characteristics. Merck Sharp & Dohme Ltd, 2001 Jan [online]. Available from URL:
[Accessed 2012 Jul 26]
US FDA. Follow-up to the March 27, 2008 communication about the ongoing safety review of montelukast (Singulair). 2009 Jan 13 [online]. Available from URL:
[Accessed 2011 Nov 11]
Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation. Chest 2005; 127: 1312–26.
Storms W. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstrinction. Expert Opinion Pharmacother 2007; 8: 2173–3287.
Knorr B, Nguyen HH, Kearins G, et al. Montelukast dose selection in children ages 2-to 5- years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol 2001; 41: 612–9.
Brocks DR, Upward JW, Georgiou P, et al. The single and multiple pharmacokinetics of pranlukast in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 303–8.
Merck & Co., Inc. Singulair (montelukast sodium): package insert. White house Station (NJ): Merck & Co., Inc., May 2010.
Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest 1998; 114: 332–4.
Montuschi P, Sala A, Dahlén S-E, et al. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today 2007; 12: 404–12.
Green RH, Pavord ID. Leukotriene antagonists and symptom control in chronic persistent asthma. Lancet 2001; 357: 1991–2.
Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147–52.
Straub DA, Moeller A, Minocchieri S, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005; 25: 289–94.
Global Initiative for Asthma (GINA) [online]. Available from URL:
[Accessed 2011 Sep 5]
Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008; 63: 5–34.
Del Giudice MM, Pezzulo A, Capristo C, et al. Leukotriene modifiers in the treatment of asthma in children. Ther Adv Respir Dis 2009; 3 (5): 245–51.
The British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: quick reference guide. May 2008, revised May 2011 [online]. Available from URL:
[Accessed 2012 Jul 26]
Spahn JD, Covar RA, Jain N, et al. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann Allergy Asthma Immunol 2006; 96: 541–9.
Bisgaard H, Zielen S, Garcia-Garcia L, et al. Montelukast reduces asthma exacerbations in 2- to 5-years old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315–22.
Van Adelsberg J, Moy J, Wei LX, et al. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005; 21: 971–9.
Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108: E48.
Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, doubleblind trial. Pediatric Montelukast Study Group. JAMA 1998; 279: 1181–6.
Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther 2008; 30: 1026–35.
Dempsey OJ. Leukotrienes receptor antagonist therapy. Postgrad Med J 2000; 76: 767–73.
Knorr B, Maganti L, Ramakrishnan R, et al. Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. J Clin Pharmacol 2006; 46:620–7.
Kearns GL, Lu S, Maganti L, et al. Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis. J Clin Pharmacol 2008; 48: 502–11.
Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003; 326: 621.
Sorkness CA, Lemanske Jr RF, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119: 64–72.
Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-tomoderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45–52.
Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233–42.
Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005; 147 (2): 213–20.
Garcia ML, Wahn U, Gilles L, et al. Montelukast compared with fluticasone, control of asthma among 6 to 14 year old patients with mild asthma: The MOSAIC Study. Pediatrics 2005; 116: 360–9.
Jartti T. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? Eur J Pediatr 2008; 167: 731–6.
Becker AB, Kuznetsova O, Vermeulen J, et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol 2006; 96: 800–7.
Pedersen S, Agertoft L, Williams-Herman D, et al. Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatr Pulmonol 2007; 42: 838–43.
Wang L, Hollenbeak CS, Mauger DT, et al. Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2011; 127(1): 161–6, 166.e1
Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364 (18): 1695–707.
Bukstein DA, Luskin AT, Bernstein A. “Real-world” effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90: 543–9.
Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2011; (5): CD003137.
Lemanske Jr RF, Mauger DT, Sorkness CA, et al. Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975–85.
Miraglia del Giudice M, Piacentini GL, Capasso M, et al. Formoterol, montelukast and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide. Respir Med 2007; 101: 1809–13.
Buchvald F, Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 2003; 91: 309–13.
Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006; (4): CD003137.
Ringdal N, Eliraz A, Prunizec R, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003; 97: 234–41.
Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma, exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2008; 327: 891–7.
Van den Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid in asthma. J Allergy Clin Immunol 2000; 106: 1209–26.
Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160: 1862–8.
Currie GP, Bates CE, Lee DK, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid treated patients with asthma. Am J Respir Crit Care Med 2003; 167: 1232–8.
Strunk RC, Bacharier LB, Phillips BR, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008; 122: 1138–44.
Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cystenil leukotriene receptor antagonist. Thorax 1997; 52: 1030–5.
Sandrini A, Ferreira IM, Gutierrez C, et al. Effects of montelukast on exaled nitric oxide and non-volatile markers of inflammation in mild asthma. Chest 2003; 124: 1334–40.
Kopriva F, Janostakova A, Jarmila S, et al. Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma. Clin Drug Investig 2006; 26: 351–6.
Strauch E, Moske O, Thomas S. A randomised controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma. Pediatr Res 2003; 54: 198–203.
Borker R, Emmett A, Jhingran P, et al. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Ann Allergy Asthma Immunol 2005 Aug; 95 (2): 181–9.
Navarro RP, Parasuraman B. Cost effectiveness of asthma controller therapies: influence of disease severity and other variables. Manag Care Interface 2005; 18 (6): 31–40.
Peroni DG, Piacentini GL, Ress M, et al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol 2002; 13:434–7.
Pajaron-Fernandez M, Garcia-Rubia S, Sanchez- Solis M, et al. Montelukast administred in the morning or evening to prevent exercise-induced bron-choconstiction in children. Ped Pulmonol 2006; 41: 222–7.
De Benedictis FM, Miraglia del Giudice M, Forenza N, et al. Lack of tolerance to the protective effect of montelukast in exercise-induced broncho-constriction in children. Eur Respir 2006; J28: 291–5.
Villaran C, O’Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 1999; 104: 547–53.
Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424–8.
Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363–8.
Melo RE, Sole D, Naspitz CK. Exercise-inducedbronchoconstriction in children: montelukast attenuates the immediate phase and late phase responses. J Allergy Clin Immunol 2003; 111: 301–17.
Robertson C, Price D, Henry R, et al. Short-course montelukast for intermittent asthma in children. Am J Respir Crit Care Med 2007; 175: 323–9.
Harmanci K, Bakirtas A, Turktas I, et al. Oral montelukast treatment of preschool-aged children with acute asthma. Ann Allergy Asthma Immunol 2006; 96: 731–5.
Nelson KA, Smith SR, Trinkaus K, et al. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years. Pediatr Emerg Care 2008; 24: 21–7.
Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008; 122: 1127–35.
Johnston NW, Mandhane P, Duncan J, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomised, controlled trial of montelukast added to usual therapy. Pediatrics 2007; 120: 702–12.
Brand P, Baraldi E, Bisgaard H, et al. Definition, assessment ant treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096–110.
Heymann PW, Carper HT, Murphy DD, et al. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 2004; 114: 239–47.
Montuschi P, Mondino C, Koch P, et al. Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. Chest 2007; 132: 1876–81.
Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol 2009; 124 (3): 417–21.
Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991 May; 143 (5 Pt 1): 1025–9.
Schäper C, Noga O, Koch B, et al. Anti-inflammatory properties of monte lukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol 2011; 21 (1): 51–8.
Park JS, Jang AS, Park SW, et al. Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics. Allergy Asthma Immunol Res 2010 Jan; 2 (1): 48–54.
White A, Ludington E, Mehra P, et al. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol 2006 Nov; 97 (5): 688–93.
Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Global Allergy and Asthma European Network. Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010 Sep; 126 (3): 466–76.
Keskin O, Alyamac E, Tuncer A, et al. Do the LTRA work in children with grass pollen-induced allergic rhinitis? Pediatr Allergy Immunol 2006; 17: 259–68.
Razi C, Bakirtas A, Harmanci K, et al. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97:767–74.
Chen ST, Lu KH, Sun HL, et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2–6 yr. Pediatr Allergy Immunol 2006; 17: 49–54.
Sazonov-Kocevar V, Laforest L, Travier N, et al. Asthma and allergy medication use and costs among pediatric primary care patients on asthma controller therapy. Pediatr Allergy Immunol 2006 Dec; 17 (8): 620–8.
Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J. Allergy Clin Immunol 2010; 125: 285–92.
Montuschi P, Mondino C, Koch P, et al. Effect of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in asthmatic children. J Allergy Clin Immunol 2006; 118: 347–53.
Rabinovitch N, Graber NJ, Chinchilli VM, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma [published erratum appears in J Allergy Clin Immunol 2010; 126: 959–60]. J Allergy Clin Immunol 2010; 126: 545–51.
Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57: 309–16.
Hoshino M, Takahashi M, Takai Y, et al. ICS decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999; 103: 1054–61.
Bisgaard H, Hermansen MN, Loland L, et al. Intermittent ICS in infants with episodic wheezing. N Engl J Med 2006; 354: 1998–2005.
Woszczek G, Chen LY, Alsaaty S, et al. Concentration-dependent non-cysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists. J Immunol 2010; 184 (4): 2219–25.
Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma [published erratum appears in Am J Respir Crit Care Med 2009; 180 (8): 796]. Am J Respir Crit Care Med 2009; 180 (5): 388–95.
Choy DF, Modrek B, Abbas AR, et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol 2011; 186(3): 1861–9.
Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365 (12): 1088–98.
PubMed CrossRef Copyright information
© Springer International Publishing AG 2012